ArticleClinical and experimental immunology2008
T cell activation profiles in Kawasaki syndrome.
Article in Clinical and experimental immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 64 citations in OpenAlex.
- A study on the transcriptional characteristics of novel HERV gene in the blood of children with Kawasaki disease and its correlation with the disease.Microbiology spectrum · 2025Article
- Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.Life (Basel, Switzerland) · 2025Review
- Blocking Superantigen-Mediated Diseases: Challenges and Future Trends.Journal of immunology research · 2024Review
- Single-cell RNA sequencing of peripheral blood mononuclear cells from acute Kawasaki disease patients.Nature communications · 2021Article
- Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report.Frontiers in medicine · 2020Article
- Biomarkers for Kawasaki Disease: Clinical Utility and the Challenges Ahead.Frontiers in pediatrics · 2019Review
- Article
- T-Helper Cytokine Profiles in Patients with Kawasaki Disease.Korean circulation journal · 2015Article
- Kawasaki disease: insights into pathogenesis and approaches to treatment.Nature reviews. Rheumatology · 2015Review
- Management of Kawasaki disease.Archives of disease in childhood · 2014Review
- The role of infection in Kawasaki syndrome.The Journal of infection · 2013Review
- Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.Clinical and experimental immunology · 2011Article
- Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease.Clinical and experimental immunology · 2010Article
- [New pathogenetic aspects in primary systemic vasculitides].Der Internist · 2009Review
- Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report.Pediatric rheumatology online journal · 2009Article
- Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment.Paediatric drugs · 2009Review
- Searching for the cause of Kawasaki disease--cytoplasmic inclusion bodies provide new insight.Nature reviews. Microbiology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superantigens (SAgs) are potent stimulators of T cells bearing specific Vbeta T cell receptors (TCR) and may play a role in the pathogenesis of Kawasaki syndrome (KS), although despite 15 years of intense study this area remains controversial. Because SAgs can cause Vbeta restricted T cell activation in the absence of Vbeta skewing the aims of this study were to describe a flow cytometric protocol to study both CD4 and CD8 Vbeta repertoires, and CD69 expression across the CD4 and CD8 Vbeta repertoire in children with KS. Sixteen children with KS were studied. There was no significant increase in overall peripheral blood CD4 or CD8 T cell activation as determined by CD69 expression. However, Vbeta restricted CD4 and/or CD8 activation was observed in eight of 11 (72%) of the KS patients, a finding not observed in healthy controls. Thirteen of 16 (81%) of the KS patients had evidence of either Vbeta skewing (particularly CD4 Vbeta2 and Vbeta5.1) and/or Vbeta restricted activation. Three patients had Vbeta restricted activation in the absence of skewing. We suggest that these preliminary observations highlight the many layers of complexity when considering T cell activation in KS, which could explain some of the conflicting studies regarding peripheral blood T cell activation and Vbeta skewing. It is likely that in order to move forward with this debate a combination of detailed microbiological, immunological and molecular techniques applied to individual patients will be required ultimately to prove or refute the SAg hypothesis of KS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.